|
US9453251B2
(en)
|
2002-10-08 |
2016-09-27 |
Pfenex Inc. |
Expression of mammalian proteins in Pseudomonas fluorescens
|
|
DE10254601A1
(de)
|
2002-11-22 |
2004-06-03 |
Ganymed Pharmaceuticals Ag |
Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
|
|
EP1774017B1
(en)
|
2004-07-26 |
2013-05-15 |
Pfenex Inc. |
Process for improved protein expression by strain engineering
|
|
AU2006328882B2
(en)
*
|
2005-12-21 |
2011-06-16 |
Amgen Research (Munich) Gmbh |
Pharmaceutical antibody compositions with resistance to soluble CEA
|
|
PT1976880T
(pt)
|
2005-12-21 |
2016-09-28 |
Amgen Res Munich Gmbh |
Composições farmacêuticas com resistência a cea solúvel
|
|
US9580719B2
(en)
|
2007-04-27 |
2017-02-28 |
Pfenex, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
|
US9394571B2
(en)
|
2007-04-27 |
2016-07-19 |
Pfenex Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
|
WO2009070642A1
(en)
*
|
2007-11-28 |
2009-06-04 |
Medimmune, Llc |
Protein formulation
|
|
GB0908613D0
(en)
|
2009-05-20 |
2009-06-24 |
Immunocore Ltd |
T Cell Reseptors
|
|
CA2774260C
(en)
|
2009-09-16 |
2018-10-09 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
|
EP2507628A4
(en)
*
|
2009-12-01 |
2013-04-24 |
Medimmune Llc |
IMPROVED METHODS AND COMPOSITIONS FOR DETECTING AND TREATING CEA-EXPRESSING TUMORS
|
|
CA2858350A1
(en)
|
2011-01-14 |
2013-07-19 |
The Regents Of The University Of California |
Therapeutic antibodies against ror-1 protein and methods for use of same
|
|
US20140242081A1
(en)
*
|
2011-07-18 |
2014-08-28 |
Micromet Ag |
Dosing regimens for treatment of cea-expressing cancers
|
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
|
WO2013162748A1
(en)
*
|
2012-04-27 |
2013-10-31 |
The Trustees Of The University Of Pennsylvania |
Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof
|
|
WO2013174404A1
(en)
*
|
2012-05-23 |
2013-11-28 |
Ganymed Pharmaceuticals Ag |
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
US20150231241A1
(en)
|
2012-08-14 |
2015-08-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
WO2014028560A2
(en)
|
2012-08-14 |
2014-02-20 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
CN105073776B
(zh)
|
2012-11-13 |
2019-04-12 |
拜恩科技股份公司 |
用于治疗表达紧密连接蛋白的癌症疾病的制剂
|
|
HRP20170743T1
(hr)
|
2012-11-20 |
2017-07-28 |
Sanofi |
Anti-ceacam5 protutijela i njihova uporaba
|
|
WO2014131712A1
(en)
*
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
JP6499087B2
(ja)
|
2013-02-26 |
2019-04-10 |
ロシュ グリクアート アーゲー |
二重特異性ｔ細胞活性化抗原結合分子
|
|
EP2970449B1
(en)
|
2013-03-15 |
2019-09-25 |
Amgen Research (Munich) GmbH |
Single chain binding molecules comprising n-terminal abp
|
|
EP2930188A1
(en)
*
|
2014-04-13 |
2015-10-14 |
Affimed Therapeutics AG |
Trifunctional antigen-binding molecule
|
|
US11427647B2
(en)
|
2014-04-27 |
2022-08-30 |
Famewave Ltd. |
Polynucleotides encoding humanized antibodies against CEACAM1
|
|
MX366359B
(es)
|
2014-04-27 |
2019-07-05 |
Ccam Biotherapeutics Ltd |
Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1).
|
|
KR20170010863A
(ko)
|
2014-07-01 |
2017-02-01 |
화이자 인코포레이티드 |
이중특이성 이종이량체성 디아바디 및 이의 용도
|
|
CA2977687C
(en)
|
2015-02-24 |
2024-02-13 |
Hwai Wen Chang |
Conditionally active proteins
|
|
CN106432502B
(zh)
*
|
2015-08-10 |
2020-10-27 |
中山大学 |
用于治疗cea阳性表达肿瘤的双特异纳米抗体
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
KR20180073561A
(ko)
|
2015-10-02 |
2018-07-02 |
에프. 호프만-라 로슈 아게 |
이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자
|
|
AU2016368469B2
(en)
|
2015-12-09 |
2023-11-02 |
F. Hoffmann-La Roche Ag |
Type II anti-CD20 antibody for reducing formation of anti-drug antibodies
|
|
AR107303A1
(es)
|
2016-01-08 |
2018-04-18 |
Hoffmann La Roche |
Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
|
|
US11827688B2
(en)
|
2016-06-02 |
2023-11-28 |
Immunocore Limited |
Dosing regimen for GP100-specific TCR—anti-CD3 SCFV fusion protein
|
|
CN107663240B
(zh)
*
|
2016-07-29 |
2021-01-12 |
中国人民解放军第四军医大学 |
高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用
|
|
CN117752798A
(zh)
|
2016-12-19 |
2024-03-26 |
豪夫迈·罗氏有限公司 |
用靶向性4-1bb(cd137)激动剂的组合疗法
|
|
KR20190099527A
(ko)
|
2017-01-03 |
2019-08-27 |
에프. 호프만-라 로슈 아게 |
항-4-1bb 클론 20h4.9를 포함하는 이중특이성 항원 결합 분자
|
|
CN107056952A
(zh)
*
|
2017-05-10 |
2017-08-18 |
常州市第人民医院 |
Cea.car‑t及其制备与应用
|
|
CN107058234B
(zh)
*
|
2017-05-12 |
2019-09-13 |
常州市第一人民医院 |
Car.il-33-t及其制备与应用
|
|
CN113896797B
(zh)
|
2017-08-01 |
2023-05-09 |
Ab工作室有限公司 |
双特异性抗体及其用途
|
|
CA3079036A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted ox40 agonists
|
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
|
EP3802599B1
(en)
|
2018-06-03 |
2023-12-20 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
|
TW202035447A
(zh)
|
2018-07-04 |
2020-10-01 |
瑞士商赫孚孟拉羅股份公司 |
新穎雙特異性促效性4-1bb抗原結合分子
|
|
MX2021007320A
(es)
|
2018-12-21 |
2021-07-07 |
Hoffmann La Roche |
Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor.
|
|
US12463463B2
(en)
|
2019-01-28 |
2025-11-04 |
Ab Therapeutics, Inc. |
Bispecific antibodies and uses thereof
|
|
SG11202107843WA
(en)
|
2019-02-07 |
2021-08-30 |
Sanofi Sa |
Use of anti-ceacam5 immunoconjugates for treating lung cancer
|
|
EP3693023A1
(en)
|
2019-02-11 |
2020-08-12 |
Sanofi |
Use of anti-ceacam5 immunoconjugates for treating lung cancer
|
|
BR112021022682A2
(pt)
|
2019-05-14 |
2022-02-22 |
Provention Bio Inc |
Métodos e composições para prevenir diabetes do tipo 1
|
|
AU2020291014B2
(en)
|
2019-06-13 |
2025-06-05 |
Bolt Biotherapeutics, Inc. |
Aminobenzazepine compounds, immunoconjugates, and uses thereof
|
|
EP3990492A1
(en)
|
2019-06-27 |
2022-05-04 |
F. Hoffmann-La Roche AG |
Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
|
|
WO2021041300A2
(en)
*
|
2019-08-23 |
2021-03-04 |
Ab Therapeutics, Inc. |
Bispecific antibodies and uses thereof
|
|
CA3148694A1
(en)
|
2019-09-03 |
2021-03-11 |
Romas Kudirka |
Aminoquinoline compounds, immunoconjugates, and uses thereof
|
|
BR112022004995A2
(pt)
|
2019-09-18 |
2022-06-21 |
Lamkap Bio Alpha AG |
Anticorpos biespecíficos contra ceacam5 e cd3
|
|
WO2021067242A1
(en)
|
2019-09-30 |
2021-04-08 |
Bolt Biotherapeutics, Inc. |
Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
|
|
KR20220088901A
(ko)
|
2019-10-25 |
2022-06-28 |
볼트 바이오테라퓨틱스 인코퍼레이티드 |
티에노아제핀 면역접합체, 및 이의 용도
|
|
WO2021098822A1
(zh)
*
|
2019-11-21 |
2021-05-27 |
江苏恒瑞医药股份有限公司 |
一种双特异性抗体
|
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
|
AR121706A1
(es)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
|
|
CA3176626A1
(en)
|
2020-05-08 |
2021-11-11 |
David Dornan |
Elastase-substrate, peptide linker immunoconjugates, and uses thereof
|
|
US12006366B2
(en)
|
2020-06-11 |
2024-06-11 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|
|
CN116234586A
(zh)
|
2020-08-13 |
2023-06-06 |
博尔特生物治疗药物有限公司 |
吡唑并氮呯免疫缀合物及其用途
|
|
US12564642B2
(en)
|
2020-11-10 |
2026-03-03 |
Sanofi |
CEACAM5 antibody-drug conjugate formulation
|
|
US20220195066A1
(en)
|
2020-12-11 |
2022-06-23 |
Bolt Biotherapeutics, Inc. |
Anti-cea immunoconjugates, and uses thereof
|
|
JP2024501453A
(ja)
|
2020-12-11 |
2024-01-12 |
ボルト バイオセラピューティクス、インコーポレーテッド |
抗ｃｅａイムノコンジュゲート、及びそれらの使用
|
|
HRP20240213T1
(hr)
|
2020-12-18 |
2024-04-26 |
Lamkap Bio Beta Ag |
Bispecifična antitijela protiv ceacam5 i cd47
|
|
TW202304520A
(zh)
|
2021-03-26 |
2023-02-01 |
美商博特生物治療公司 |
２－胺基－４－羧醯胺－苯并氮呯免疫結合物及其用途
|
|
CN117940168A
(zh)
|
2021-03-26 |
2024-04-26 |
博尔特生物治疗药物有限公司 |
2-氨基-4-甲酰胺-苯并氮杂䓬免疫缀合物及其用途
|
|
WO2022251253A1
(en)
|
2021-05-24 |
2022-12-01 |
Provention Bio, Inc. |
Methods for treating type 1 diabetes
|
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
|
KR20250024741A
(ko)
|
2022-03-23 |
2025-02-19 |
시나픽스 비.브이. |
암배아성 항원을 발현하는 종양을 표적화하기 위한 항체-컨쥬게이트
|
|
CN119998319A
(zh)
|
2022-06-16 |
2025-05-13 |
拉姆卡普生物测试有限公司 |
针对ceacam5和cd47的双特异性抗体与针对ceacam5和cd3的双特异性抗体的组合治疗
|
|
KR20250173599A
(ko)
|
2023-03-14 |
2025-12-10 |
젠코어 인코포레이티드 |
항-cd28 조성물
|
|
AU2024311339A1
(en)
|
2023-06-21 |
2026-01-08 |
F. Hoffmann-La Roche Ag |
Combination therapy with fap-targeted lymphotoxin beta receptor agonists
|
|
CN121248779A
(zh)
*
|
2024-06-25 |
2026-01-02 |
冕屹立生物技术(上海)有限公司 |
靶向人cd3分子的抗体及其应用
|